Document Detail

In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats.
MedLine Citation:
PMID:  15117889     Owner:  NLM     Status:  MEDLINE    
Increased circulating and cardiac TNF-alpha levels during myocardial ischemia have been found in both experimental animals and patients with ischemic heart disease and advanced heart failure. Soluble TNF-alpha receptor 1 (sTNFR1) is an antagonist to TNF-alpha. In the present study, we examined whether sTNFR1 improves cardiac function in rats after myocardial infarction. Male Wistar rats were subjected to left coronary artery (LCA) ligation. Immediately after the ligation, a total of 200 microg of either the sTNFR1 or LacZ plasmid was injected into three different sites in the left ventricular wall. From 1 to 21 days after LCA ligation, TNF-alpha bioactivity in the heart was higher in rats receiving LacZ plasmid than in sham-operated rats, whereas sTNFR1 plasmid significantly suppressed the increase. The LV diastolic dimension was significantly lower, and the fractional shortening was significantly higher in rats treated with the sTNFR1 plasmid than in those treated with the LacZ plasmid. At 21 days after LCA ligation, the LV end-diastolic pressure was also significantly lower in the rats treated with the sTNFR1 plasmid. In addition, the sTNFR1 expression plasmid had significantly reduced the infarct size. In conclusion, TNF-alpha bioactivity in the heart increased during the early stage of infarction and remained elevated. This elevation seemed partially responsible for the impairment of LV function and the increased infarct size. Suppression of TNF-alpha bioactivity from the early stage of infarction with the sTNFR1 plasmid improved cardiac function and reduced infarct size.
Masahiro Sugano; Keiko Tsuchida; Tomoji Hata; Naoki Makino
Related Documents :
14670809 - High levels of myocardial antioxidant defense in aging nondiabetic normotensive zucker ...
20579749 - Oestradiol supplement minimises coronary occlusion-induced myocardial infarction and ve...
18808529 - Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocar...
9074699 - Relationship between passive tissue strain and collagen uncoiling during healing of inf...
2959259 - Myocardial contractility and left ventricular myosin isoenzyme pattern in cardiac hyper...
11984749 - The renin-angiotensin system does not contribute to the endothelial dysfunction and inc...
7388859 - Migration of 15 micron microspheres from infarcted myocardium.
11571249 - Short-term local delivery of an inhibitor of ras farnesyltransferase prevents neointima...
11323779 - Renal infarct: contrast-enhanced power doppler sonographic findings.
Publication Detail:
Type:  Journal Article     Date:  2004-03-19
Journal Detail:
Title:  FASEB journal : official publication of the Federation of American Societies for Experimental Biology     Volume:  18     ISSN:  1530-6860     ISO Abbreviation:  FASEB J.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-30     Completed Date:  2004-09-28     Revised Date:  2012-02-15    
Medline Journal Info:
Nlm Unique ID:  8804484     Medline TA:  FASEB J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  911-3     Citation Subset:  IM    
Department of Molecular and Cellular Biology, Division of Molecular and Clinical Gerontology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu, Oita, 874-0838, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / genetics,  physiology*
Coronary Vessels
Drug Evaluation, Preclinical
Gene Therapy*
Genetic Vectors / administration & dosage,  therapeutic use*
Heart Ventricles / ultrasonography
Injections, Intralesional
Myocardial Infarction / pathology,  physiopathology,  therapy*,  ultrasonography
Myocardium / pathology
Protein Structure, Tertiary
RNA, Messenger / biosynthesis
Rats, Wistar
Receptors, Tumor Necrosis Factor / genetics,  physiology*
Receptors, Tumor Necrosis Factor, Type I
Recombinant Fusion Proteins / genetics,  physiology
Reverse Transcriptase Polymerase Chain Reaction
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Ventricular Function, Left
Reg. No./Substance:
0/Antigens, CD; 0/RNA, Messenger; 0/Receptors, Tumor Necrosis Factor; 0/Receptors, Tumor Necrosis Factor, Type I; 0/Recombinant Fusion Proteins; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression an...
Next Document:  Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uter...